Improving the quality of life for patients with functional mitral regurgitation

GizaVC invests in the vision of most innovative entrepreneurs.


Mitralign is developing an innovative catheter-based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system  rivals surgical annuloplasty.

Mitralign 164X55 color



CEO: Rick Geoffrion         

Giza's Team Member

Yuval Avni



Fields of invesment: icon lifeHealthcare

Contact info: Website